TAK-279: Clinical Trials

5 recruiting, 2 completed, 1 active not recruiting. 8 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	8	Recruiting 5, Completed 2, Active not recruiting 1

Follow TAK-279: new trials by email Literature Review of TAK-279 trials Research Report on TAK-279

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease Zasocitinib - Crohn's Disease	Phase 2	Recruiting	Takeda	20	2026-08-13	2026-08-24
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa Zasocitinib (Dose A), Placebo - Hidradenitis Suppurativa	Phase 2	Recruiting	Takeda	90	2026-01-26	2026-03-06
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo Zasocitinib, Placebo - Nonsegmental Vitiligo	Phase 2	Recruiting	Takeda	200	2025-11-03	2026-09-30
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) Zasocitinib - Crohn's Disease, Ulcerative Colitis	Phase 2	Recruiting	Takeda	192	2025-05-28	2026-05-22
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis TAK-279, Placebo - Ulcerative Colitis	Phase 2	Active not recruiting	Takeda	213	2024-03-29	2026-08-17
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease TAK-279, Placebo - Crohn's Disease	Phase 2	Recruiting	Takeda	268	2024-03-05	2026-09-25
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis NDI-034858, Placebo - Psoriatic Arthritis	Phase 2	Completed	Takeda	305	2022-01-06	2024-05-31
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis NDI-034858 study drug, Placebo - Moderate to Severe Plaque Psoriasis	Phase 2	Completed	Takeda	259	2021-08-11	2023-09-28

Conditions studied

Crohn Disease (3)  ·  Colitis, Ulcerative (2)  ·  Arthritis, Psoriatic (1)  ·  Hidradenitis Suppurativa (1)

Sponsors

Takeda (8)

Countries

United States (7)  ·  Poland (6)  ·  Canada (5)  ·  China (5)  ·  Czechia (4)  ·  France (4)  ·  Germany (4)  ·  Australia (3)  ·  Hungary (3)  ·  Italy (3)  ·  Japan (3)  ·  Netherlands (3)  ·  Slovakia (3)  ·  South Korea (3)  ·  United Kingdom (3)

Results publications

PMID 39167366, PMID 42143206, PMID 42740479

NIH funding

2023 (2), 2025 (2)